ACTUALIZACIÓN DEL TRATAMIENTO DE LA POLINEUROPATÍA DIABÉTICA PERIFÉRICA DOLOROSA 2015. COMITÉ DE NEUROPATÍA DIABÉTICA. SOCIEDAD ARGENTINA DE DIABETES
Resumen
La diabetes es una enfermedad crónica y progresiva que se asocia a complicaciones potencialmente discapacitantes, entre ellas, la neuropatía diabética es probablemente la afectación sintomática más frecuente con importante impacto social y económico. El tratamiento de la neuropatía somática dolorosa y del sistema nervioso autónomo ha sido un desafío durante años. Nuevas terapéuticas se encuentran disponibles, las cuales mejoran el dolor y brindan esperanza de lograr alivio a personas que padecen esta complicación.
Palabras clave
Texto completo:
PDFReferencias
Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Pain. 1990; 40(1):105-107.
Moss SE, et ál. WESDR. Arch. Intern. Med. 1992; 152: 610-616.
DCCT Research Group. N. Engl. J. of Med. 1993; 329: 977-986.
Ohkubo Y, et ál. Diabetes Res. Clin. Pract. 1995; 28: 103-117.
Turner RC, Holman RR, Cull CA, et ál. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998: 352; (9131): 837-853.
Tammy JL, Blake CR, Vincent S, et ál. Treating diabetic peripheral neuropathic pain. Saint Louis University Family Medicine Residency Program, Belleville, Illinois. American Family Physician. 2010; 82, (2): 151-158.
Brownlee M. Metabolism. 2000; 49 (2 sppl 1): 9-13.
Greene DA, et ál. N. Engl. J. Med. 1987; 316:599-606.
Javed S, Malik R. Therapeutic Advances in Chronic Disease 2015; 6(1): 15-28.
Albers JW, Herman WH, PopBusui R, et ál. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33, (5): 1090-1096.
PopBusui R, Low PA, Waberski BH, et ál. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation 2009; 119, (22): 2886-2893.
Patel A, MacMahon S, Chalmers J, et ál. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N. Engl. J. Med. 2008; 358 (24): 2560-2572.
Duckworth W, Abraira C, Moritz T, et ál. Glucose control and vascular complications in veterans type 2 diabetes. VADT Investigators. N. Eng. J. Med 2009; 360 (2): 129-139.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et ál. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials. BMJ 2011; 343: d4169.
Callaghan B, Little A, Feldman E, et ál. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev 6: CD007543.
Sociedad Argentina de Diabetes. Guías de práctica clínica para el manejo de la diabetes tipo 1. Buenos Aires, 2006.
Ziegler D. Treatment of diabetic neuropathy and neuropathy pain: How far have we come? Diabetes Care 31 (Suppl. 2): S255-261, 2008.
Fioretto P, Steffes M, Sutherland D, et ál. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. Med. 1998; 339: 69-75.
Vincent A, Callaghan B, Smith A, et ál. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 2011; 7: 573-583.
Ametov AS, Barinov A, Dyck PJ, et ál. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776.
Ruhnau KJ, Meissner HP, Finn R, et ál. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med. 1999; 16 (12): 1040-1043.
Ziegler D, Hanefeld M, Ruhnau KJ, et ál. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38:1425-1433.
Reljanovic M, Reichel G, Rett K, et ál. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy free radic. Res. 1999 31 (3): 171-179.
Ziegler D, et ál. Oral treatment with alfa lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29:2365-70.
Ziegler D, et ál. Antioxidant treatment with alpha lipoic acid in diabetic polyneuropathy. A 4-yearsrandomiseddoublé-blinded trial (NATHAN 1 Study). Diabetologia 2007, 50; Suppl 1, S63.
Ziegler D, Nowak H, Kempler P, et ál. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 21: 114-121.
Ziegler D, et ál. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32:1479-1484.
Ziegler D. Current concepts in the management of diabetic polyneuropathy. Current Diabetes Reviews 2011; 7: 208 220.
Hammes H, Du X, Edelstein D, et ál. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003 9: 294-299.
Stracke H, Gaus W, Achenbach U, et ál. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled Clinical Study. Exp. Clin. Endocrinol. Diabetes 2008; 116: 600-605.
Boulton A, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy. Diabetes Metab. Res. Rev. 2013; 29: 327-333.
Goto Y, Hotta N, Shigeta Y, et ál. Effects of aldose reductase inhibitor, epalrestat, on diabetic neuropathy, clínic benefits and indications for the drug assessed from the results of a placebo-controlled double blind study. Biomed. Pharmacother 1995; 49: 269-277.
Hotta N, Akanuma Y, Kawamori R, et ál. Long term clinical effects of epalrestat, and aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 2006; 29:1538-1544.
Keen H, Payan J, Allawi J, et ál. Treatment of diabetic neuropathy with linolenic acid. Diabetes Care 1993;16:8-15.
Scafidi S, Fiskum G, Lindauer SL, et ál. Metabolism of acetil-carnitine for energy and neurotransmiter synthesis in the immature rat brain. J. Neurochem. 2010; 114: 820-831.
Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacoter. 2008; 42: 1686-1691.
Finnerup NB, Otto M, McQuay HJ, et ál. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
Max MB, Lynch SA, Muir J, et ál. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 1992; 326: 1250-1256.
Ulugol A, Karadag HC, Tamer M. Involvement of adenosine in the antiallody nice effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci. Lett. 2002; 328: 129-132.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2007; 4: CD005454.
US Food and Drug Administration. Medication guide: Pamelor, http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf (accessed 27 April 2014).
Moulin DE, Clark AJ, Gilron I, et ál. Pharmacological management of chronic neuropathic pain-consensus statementand guidelines from the Canadian Pain Society. Pain Res. Manag. 2007; 12: 13-21.
Gilron I, Bailey JM, Tu D, et ál. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252-1261.
Morello CM, Leckband SG, Stoner CP, et ál. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. 1999; 159: 1931-1937.
Sima AA, Calvani M, Mehra M, et ál. Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28: 89-94.
National Institute for Health and Clinical Excellence. Neuropathic pain-pharmacological management: the farmacological management of neuropathic pain in adults in non-speciallist settings. 2013.
Vinik A, et ál. Evidence based management of diabetes. 2012. Chapter 19, 348-349.
Vinik A, Caselli C, Nevoret ML. Endotext. Diabetic neuropathy. Last Update: august 2015.
Kajdasz DK, Iyengar S, Desaiah D, et ál. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin. Ther. 2007; 29 Suppl: 2536-2546.
Wernicke JF, Pritchett YL, D’Souza DN, et ál. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420.
Quilici S, Chancellor J, Lothgren M, et ál. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 2009; 9: 6. doi: 10.1186/1471-2377-9-6.
Montfort EG, Witte AP, Ward K. Neuropathic pain: a review of diabetic neuropathy. US Pharm 2010; 35: HS8-HS15.
Hardy T, Sachson R, Shen S, et ál. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21-26.
Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont ) 2008; 5: 16-19.
Effexor XR (venlafaxine extended release) prescribing information. Philadelphia,Pennsylvania: Wyeth Pharmaceuticals, Inc.; February 2015.
La Roche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291: 605-14. 128,132.
Lesser H, Sharma U, LaMoreaux L, et ál. Pregabalin relieves symptoms of painfuldiabetic neuropathy: a randomized controlled trial. Neurology 2004; 63:2104-10.
Richter RW, Portenoy R, Sharma U, et ál. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 2005; 6: 253-60.
Moulin DE, Boulanger A, Clark AJ, et ál. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 2014; 19(6):328-335.
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448-54.
Backonja M, Beydoun A, Edwards KR, et ál. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA.1998;280:1831-1836.
DeToledo JC, Toledo C, De Cerce J, et ál. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 1997;19:394-396.
Gilron I, Bailey JM, Tu D, et ál. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 2005; 352:1324-1334.
Schreiber AK, Nones CF, Reis RC, et ál. Diabetic neuropathic pain: Physiopathology and treatment. World J. Diabetes 2015 April 15; 6(3): 432-444.
Kalso E. Sodium channel blockers in neuropathic pain. Curr. Pharm. Des. 2005; 11:3005-3011.
Vinik AI. Diabetic neuropathies: endpoints in clinical research studies. In: Le Roith D, Vinik AI, editors. Controversies in treating diabetes: clinical and research aspects (Contemporary Endocrinology). Totowa, NJ: Human Press; 2008:135-156.
Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst. Rev. 2006;(3):CD006146.
Watson CP, Moulin D, Watt-Watson J, et ál. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1-2):71-78.
Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J. Pain Symptom Manage 2000; 19:S21-S25.
Schwartz S, Etropolski M, Shapiro DY, et ál. Safety and efficacy of tapentadol in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr. Med. Res. Opin. 2011;27:151-162.
Harati Y, Gooch C, Swenson M, et ál. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-1846.
Cummins TR. Setting up for the block: the mechanism underlying lidocaine’s use-dependent inhibition of sodium channels. J. Physiol. 2007; 582 (Pt 1): 11.
Rosenberg CJ, Watson JC. Treatment of painful diabetic peripheral neuropathy. Prosthetics and Orthotics International 2015, Vol. 39 (1) 17- 28.
Cohen K, Shinkazh N, Frank J, et ál. Pharmacological treatment of diabetic peripheral neuropathy. P&T®, June 2015, Vol. 40 Nº 6.
American Academy of Neurology. AAN summary of evidence-based guidelines for clinicians: treatment of painful diabetic neuropathy. 2011. Availableat: https://www.aan.com/Guidelines/home/GetGuidelineContent/480. Accessed March 13, 2015.
Montfort EG, Witte AP, Ward K. Neuropathic pain: a review of diabetic neuropathy. US Pharm 2010; 35:HS8-HS15.
Flores MP, de Castro APCR, Nascimento JDS. Topical analgesics. Rev. Bras. Anestesiol. 2012; 62:244-252.
Ho K, Huh BK, White WD, et ál. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin. J. Pain 2008;24:51-55.
Lynch ME, Clark AJ, Sawynok J, et ál. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 2005; 103:140-146.
Estebe JP, Myers RR. Amitriptyline neurotoxicity: dose-related pathology after topical application to rat sciatic nerve. Anesthesiology 2004; 100:1519-1525.
Piovesan EJ, Teive HG, Kowacs PA, et ál. An open study of botulinum. A toxin treatment of trigeminal neuralgia. Neurology 2005; 65:1306-1308.
Tsai CP, Liu CY, Lin KP, et ál. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. Clin. Drug Investig. 2006; 26:511-515.
Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin. J. Pain 2008; 24:731-733.
Tesfaye S. Painful diabetic neuropathy. Aetiology and non pharmacological treatment. In: Veves A, editor. Clinical management of diabetic neuropathy. Totowa (NJ): Human Press; 1998. p. 369-86.
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-1261.
Tesfaye S, Vileikyte L, Rayman G, et ál. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab. Res. Rev. 2011;27:629-638.
Lexi-Comp [online reference library]. Hudson, Ohio: American Pharmaceu-tical Association; 2009. Updated daily. http://online.lexi.com (subscription required). Accessed October 27, 2009.
Boyer EW, Shannon M. The serotonin syndrome [published corrections appear in N Engl J Med. 2009;361(17):1714 and N Engl J Med. 2007; 356:(23):2437]. N. Engl. J. Med. 2005;352(11):1112-1120.
Gore M, Sadosky A, Leslie D, et ál. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Mediplus databases. Pain Pract. 2008; 8(4):253-262.
Burke JP, Sanchez RJ, Joshi AV, et ál. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2012; 12:209-218.
De Salas-Cansado M, Perez C, Saldana MT, et ál. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes. Epub May 15, 2012.
Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J. Pain Palliat Care Pharmacother. 2012; 26:153-164.
Tesfaye S, Vileikyte L, Rayman G, et ál. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab. Res. Rev. 2011; 27:629-638.
Vinik A. The approach to the management of the patient with neuropathic pain. J. Clin. Endocrinol. Metab. 2010; 95:4802-4811.
Bril V, England J, Franklin GM, et al. Evidence based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758-1765.
Argoff C, Backonja M, Belgrade M, et ál. Consensus guidelines: treatment and planning options: diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006; 81 (suppl):S12-S25.
Tan T, Barry P, Reken S, et ál. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010; 340:c1079.
Javed S, Petropoulos LN, Alam U, et ál. Treatment of painful diabetic neuropathy. Ther. Adv. Chronic. Dis. 2015, Vol. 6 (1) 15-28.
Summary of evidence-based Guideline for Clinicians treatment of painful diabetic neuropathy. American Academy of Neurology (AAN) guideline update regarding pharmacologic and nonpharmacologic treatment of painful diabetic neuropathy (PDN) 2011.
DOI: http://dx.doi.org/10.47196/diab.v50i1.77
Copyright (c) 2018 Revista de la Sociedad Argentina de Diabetes (SAD) - Versión de prueba